ANI Pharmaceuticals, Inc.
ANIP
$82.72
-$0.05-0.06%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -3.88% | 8.45% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -3.88% | 8.45% | |||
| Cost of Revenue | -6.67% | 7.37% | |||
| Gross Profit | -1.98% | 9.20% | |||
| SG&A Expenses | -10.49% | 7.91% | |||
| Depreciation & Amortization | -7.49% | -0.08% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -8.59% | 6.28% | |||
| Operating Income | 30.64% | 27.53% | |||
| Income Before Tax | 27.77% | -6.87% | |||
| Income Tax Expenses | 168.96% | -44.47% | |||
| Earnings from Continuing Operations | 7.28% | 3.28% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 7.28% | 3.28% | |||
| EBIT | 30.64% | 27.53% | |||
| EBITDA | 14.14% | 13.90% | |||
| EPS Basic | 6.86% | 3.56% | |||
| Normalized Basic EPS | 30.11% | 43.29% | |||
| EPS Diluted | 8.88% | 3.42% | |||
| Normalized Diluted EPS | 32.95% | 43.06% | |||
| Average Basic Shares Outstanding | 1.10% | 3.05% | |||
| Average Diluted Shares Outstanding | -1.06% | 3.23% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -1.00% | |||